{"id":36542,"date":"2021-01-15T18:01:00","date_gmt":"2021-01-15T16:01:00","guid":{"rendered":"https:\/\/www.ipsen.com\/?post_type=press_release&#038;p=36542"},"modified":"2023-08-31T08:02:07","modified_gmt":"2023-08-31T06:02:07","slug":"toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/","title":{"rendered":"TOXINS 2021 : de nouvelles analyses de donn\u00e9es issues d\u2019\u00e9tudes pivotales de Phase III mettent en \u00e9vidence la dur\u00e9e d\u2019action prolong\u00e9e de Dysport\u00ae (abobotulinumtoxinA) dans cinq indications th\u00e9rapeutiques"},"content":{"rendered":"<ul>\n<li style=\"margin-bottom:3px\">Des analyses de donn\u00e9es d\u2019\u00e9tudes pivotales sur Dysport\u00ae\u00a0r\u00e9v\u00e8lent qu\u2019une grande proportion des patients n\u2019ont pas eu besoin de re-traitement pendant 12\u00a0semaines ou plus (16 semaines ou plus pour la spasticit\u00e9 des membres sup\u00e9rieurs chez l\u2019enfant).<\/li>\n<li style=\"margin-bottom:3px\">Les nouvelles analyses ont montr\u00e9 que Dysport\u00ae\u00a0apporte une longue dur\u00e9e de r\u00e9ponse.<\/li>\n<li style=\"margin-bottom:3px\">Ces donn\u00e9es constituent l\u2019un des 26 abstracts pr\u00e9sent\u00e9s par Ipsen lors du Congr\u00e8s TOXINS 2021, qui se d\u00e9roulera dans un format virtuel du 16 au 17 janvier 2021. Les d\u00e9couvertes pr\u00e9sent\u00e9es lors de ce congr\u00e8s apportent de nouvelles perspectives en termes de recherche, de d\u00e9veloppement et de fabrication, y compris des b\u00e9n\u00e9fices cliniques et \u00e9conomiques dans la prise en charge de la dystonie cervicale et de la spasticit\u00e91-28.<\/li>\n<\/ul>\n<p><b>Paris, France,\u00a0<\/b>le 15 janvier 2021 \u2014 Ipsen (Euronext\u00a0: IPN\u00a0; ADR\u00a0: IPSEY) a annonc\u00e9 les r\u00e9sultats de nouvelles analyses de donn\u00e9es d\u2019\u00e9tudes cliniques pivotales de Phase III \u00e9valuant les intervalles d\u2019injection de Dysport\u00ae\u00a0sur des cycles de traitement r\u00e9p\u00e9t\u00e9s (abobotulinumtoxinA [aboBoNT-A]) dans cinq populations de patients.\u00a0<em>\u00ab\u00a0AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations\u00a0\u00bb<\/em>\u00a0sera pr\u00e9sent\u00e9 lors du Congr\u00e8s TOXINS\u00a02021, organis\u00e9 par l\u2019<em>International Neurotoxin Association<\/em>\u00a0du 16 au 17\u00a0janvier 2020 dans un format virtuel1-28. Ipsen partagera 26 abstracts \u00e0 l\u2019occasion du congr\u00e8s, comprenant des mises \u00e0 jour d\u2019\u00e9tudes r\u00e9cemment publi\u00e9es sur l\u2019exp\u00e9rience des patients et des soignants, des donn\u00e9es de l\u2019essai de Phase IV ULIS-III, et dix abstracts issus de la recherche fondamentale sur les neurotoxines1-27.<\/p>\n<p>La spasticit\u00e9 est l\u2019une des pathologies les plus courantes et les plus invalidantes associ\u00e9es \u00e0 de nombreux troubles neurologiques chez l\u2019adulte. Elle se caract\u00e9rise par une exag\u00e9ration vitesse-d\u00e9pendante du tonus musculaire. La spasticit\u00e9 se traduit par une raideur musculaire qui entra\u00eene une invalidit\u00e9 \u00e0 plusieurs niveaux, y compris des troubles de la mobilit\u00e9 et des difficult\u00e9s \u00e0 utiliser les mains, des douleurs, une d\u00e9figuration et des contractures.29<\/p>\n<p>Les nouvelles analyses des donn\u00e9es d\u2019\u00e9tudes cliniques pivotales de Phase III comprenaient des essais cliniques randomis\u00e9s et des \u00e9tudes d\u2019extension en ouvert \u00e9valuant les intervalles d\u2019injection de Dysport\u00ae\u00a0sur des cycles de traitement r\u00e9p\u00e9t\u00e9s dans la prise en charge de la dystonie cervicale (CD), de la spasticit\u00e9 des membres inf\u00e9rieurs (ALL) et sup\u00e9rieurs (AUL) chez l\u2019adulte, et de la spasticit\u00e9 des membres inf\u00e9rieurs (PLL) et sup\u00e9rieurs (PUL) chez l\u2019enfant. La flexibilit\u00e9 du protocole des \u00e9tudes a permis \u00e0 de nombreux patients de ne pas recevoir de nouvelle injection avant la semaine\u00a012 (semaine 16 pour l\u2019indication PUL), selon les besoins cliniques.1<\/p>\n<p>Les r\u00e9sultats issus des cinq populations de patients ont d\u00e9montr\u00e9 que Dysport\u00ae\u00a0apportait une longue dur\u00e9e de r\u00e9ponse lorsqu\u2019il \u00e9tait inject\u00e9 \u00e0 la dose recommand\u00e9e et approuv\u00e9e. Une grande proportion de patients n\u2019ont pas eu besoin de re-traitement pendant plus de 12 \u00e0 16 semaines (% de patients ayant re\u00e7u une injection \u00e0 la semaine 16 ou plus tard)\u00a0: dans l\u2019\u00e9tude sur l\u2019indication CD\u00a0: 72,6-81,5\u00a0%, \u00e9tude sur l\u2019indication ALL : 20,1-32,0\u00a0%, \u00e9tude sur l\u2019indication AUL : 24,0-36,9\u00a0%, \u00e9tudes sur l\u2019indication PLL\u00a0: (72,8-93,8\u00a0%\u00a0; (% d\u2019enfants n\u2019ayant pas re\u00e7u de nouvelle injection avant la semaine 22 dans l\u2019\u00e9tude sur l\u2019indication PUL\u00a0: 19,6-67,0\u00a0%) dans les cinq \u00e9tudes pivotales sur Dysport\u00ae, avec des r\u00e9sultats de tol\u00e9rance conformes aux attentes.1<\/p>\n<p>Les r\u00e9sultats observ\u00e9s lors des \u00e9tudes cliniques de Phase III d\u2019Ipsen ont \u00e9t\u00e9 \u00e9tay\u00e9s par les donn\u00e9es en vie r\u00e9elle de l\u2019\u00e9tude observationnelle ULIS-III \u2014 la plus grande \u00e9tude de ce genre \u00e9valuant une approche clinique structur\u00e9e dans la d\u00e9finition des objectifs et la mesure des r\u00e9sultats.<\/p>\n<p>Le Docteur Alberto Esquenazi, chercheur au\u00a0<em>Sheerr Gait and Motion Analysis Laboratory\u00a0<\/em>sur le campus MossRehab aux \u00c9tats-Unis, et auteur principal et investigateur principal de l\u2019\u00e9tude, a comment\u00e9\u00a0: \u00ab\u00a0<em>La diminution du soulagement des sympt\u00f4mes peut entra\u00eener une douleur et des difficult\u00e9s de mouvement entre les traitements.<\/em>\u00a0<em>Ces donn\u00e9es ont d\u00e9montr\u00e9 que la dur\u00e9e de r\u00e9ponse de Dysport\u00ae\u00a0diminue le risque de r\u00e9cidive des sympt\u00f4mes avant la prochaine injection.\u00a0<\/em>\u00bb<\/p>\n<p>\u00ab\u00a0<em>Nous nous effor\u00e7ons constamment de d\u00e9couvrir de nouvelles possibilit\u00e9s dans l\u2019usage th\u00e9rapeutique des toxines botuliques, y compris sur des aspects cl\u00e9s du traitement tels que la dur\u00e9e de r\u00e9ponse,\u00a0\u00bb\u00a0<\/em>a d\u00e9clar\u00e9 le Docteur Steven Hildemann, Vice-Pr\u00e9sident Ex\u00e9cutif, Chief Medical Officer, Responsable des Affaires m\u00e9dicales Monde et de la S\u00e9curit\u00e9 des Patients, Ipsen. \u00ab<em>\u00a0L\u2019\u00e9tendue des donn\u00e9es que nous partagerons lors du Congr\u00e8s TOXINS 2021 soulignent l\u2019engagement d\u2019Ipsen \u00e0 faire progresser la science et \u00e0 comprendre l\u2019impact r\u00e9el de la spasticit\u00e9 et de la dystonie pour apporter des traitements aux b\u00e9n\u00e9fices individuels et cliniques.<\/em>\u00a0\u00bb<\/p>\n<p>Suivez Ipsen sur Twitter via @IpsenGroup et tenez-vous au courant des informations et actualit\u00e9s du Congr\u00e8s TOXINS 2021 en utilisant le hashtag #ina_toxins.<\/p>\n<p><b>Aper\u00e7u des pr\u00e9sentations Ipsen lors du Congr\u00e8s TOXINS 2021<\/b><b>1-27\u00a0<\/b><b>:<\/b><\/p>\n<table style=\"border-collapse: collapse;width:652px;border-collapse:collapse\">\n<tr>\n<td><b>Titre de l\u2019abstract<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations<\/b><br \/>\nAlberto Esquenazi, Mauricio R. Delgado, Robert A. Hauser, Andreas Lysandropoulos, Jean-Michel Gracies<\/td>\n<\/tr>\n<tr>\n<td><b>The Systematic Approach to Developing a Cell-Free Platform Process for Recombinant Toxin Production<\/b><br \/>\nWilliams Olughu, Kevin Moore, Cillian Paget, David Gruber<\/td>\n<\/tr>\n<tr>\n<td><b>Digitisation of Toxin Development<\/b><br \/>\nAlison Mason, Sian Richardson, Alina Bugajewska-Waller, David Gruber<\/td>\n<\/tr>\n<tr>\n<td><b>Automated fermentation platform for Toxin-based Therapeutics<\/b><br \/>\nStanislav Pepeliaev<\/td>\n<\/tr>\n<tr>\n<td><b>Quantity of Prabotulinumtoxin Type A in 100U vials<\/b><br \/>\nDavid Allcock, Andrew Splevins, Hamzah Baig, Daniel Higazi<\/td>\n<\/tr>\n<tr>\n<td><b>3D reconstruction and analysis of neuromuscular junction distribution in whole skeletal muscles in the rat using light-sheet microscopy<\/b><br \/>\nDenis Carr\u00e9, Renaud Morin, Marine Norlund, Aur\u00e9lie Gomes, Jean-Michel Lagarde, Stephane Lezmi<\/td>\n<\/tr>\n<tr>\n<td><b>BoNT Intoxication: Functional Genomics Reveals an Unexpected Trafficking Route<\/b><br \/>\nJeremy Yeo, Omar Loss, Iwona Ziomkiewicz, Johannes Krupp, Felicia Tay, Keith Foster, Matthew Beard, Frederic Bard<\/td>\n<\/tr>\n<tr>\n<td><b>Effects of recombinant botulinum neurotoxin type A1 on CFA-induced mechanical allodynia and sensory neurone responses to mechanical stimulation monitored with GCaMP fluorescence in mice<\/b><br \/>\nBeatrice Oehler, Cindy Perier, Amy Fisher, Mikhail Kalinichev and Stephen McMahon<\/td>\n<\/tr>\n<tr>\n<td><b>Management of Symptom Re-Emergence in Patients Living with Spasticity and Cervical Dystonia: Findings from 2 Online Patient Surveys<\/b><br \/>\nAlberto Esquenazi, Joaquim J. Ferreira, Jorge Jacinto, Andreas Lysandropoulos, Cynthia Comella<\/td>\n<\/tr>\n<tr>\n<td><b>Patients Experiences of Symptom Re-Emergence: Findings from 2 Online Patient Surveys in Spasticity and Cervical Dystonia<\/b><br \/>\nAlberto Esquenazi, Joaquim J. Ferreira, Jorge Jacinto, Andreas Lysandropoulos, Cynthia Comella<\/td>\n<\/tr>\n<tr>\n<td><b>Patient Perceptions of Spasticity and Treatment Satisfaction Over the Course of a Botulinum Neurotoxin A (BoNT-A) Treatment Cycle: An Ethnographic Study of Stroke Survivors<\/b><br \/>\nJorge Jacinto, Andreas Lysandropoulos, Antony Fulford Smith<\/td>\n<\/tr>\n<tr>\n<td><b>Longitudinal Goal Attainment with Integrated Upper Limb Spasticity Management Including Botulinum Toxin A: Primary Results from the ULIS-III Study<\/b><br \/>\nLynne Turner-Stokes, Klemens Fheodoroff, Jorge Jacinto, Allison Brashear, Pascal Maisonobe, Andreas Lysandropoulos, Stephen Ashford<\/td>\n<\/tr>\n<tr>\n<td><b>Real-Life Data on the Time to Retreatment with Botulinum Toxin A in Upper Limb Spasticity Management<\/b><br \/>\nJorge Jacinto, Stephen Ashford, Klemens Fheodoroff, Allison Brashear, Pascal Maisonobe, Andreas Lysandropoulos, Lynne Turner-Stokes<\/td>\n<\/tr>\n<tr>\n<td><b>Pain in Cervical Dystonia: A Meta-Analysis of Outcomes Following Treatment with AbobotulinumtoxinA in Randomized, Controlled Clinical Studies<\/b><br \/>\nRaymond L. Rosales, Lorraine Cuffe, Benjamin Regnault, Richard M Trosch<\/td>\n<\/tr>\n<tr>\n<td><b>Impact of patient input on the study execution of an observational study assessing the effectiveness of abobotulinumtoxinA treatment in leg spasticity management in adults<\/b><br \/>\nAlberto Esquenazi, Pascal Maisonobe, Carlos Dur\u00e1n S\u00e1nchez, Andreas Lysandropoulos, Stephen Ashford<\/td>\n<\/tr>\n<tr>\n<td><b>Improvement of Spastic Paresis and Cervical Dystonia Management: Assessment of Seven Years of the Innovative International Educational Program Ixcellence Network<\/b><b>\u00ae<\/b><br \/>\nNigar Dursun, Tae Mo Chung, Carlo Colosimo, Roongroj Bhidayasiri, Kailash Bhatia, Julie Tiley, Jorge Jacinto<\/td>\n<\/tr>\n<tr>\n<td><b>Long-Term Efficacy and Safety of Liquid Formulation AbobotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Placebo-Controlled and Open-Label Repeat Injection Study<\/b><br \/>\nPhilippe Kestemont, Said Hilton, Bill Andriopoulos, Inna Prygova, Catherine Thompson, Magali Volteau, Benjamin Ascher<\/td>\n<\/tr>\n<tr>\n<td><b>Patient satisfaction with abobotulinumtoxinA for aesthetic use in the upper face: A Systematic literature review and post hoc analysis of the APPEAL study<\/b><br \/>\nRiekie Smit, Elena Gubanova, Joely Kaufman, Marina Landau, Beatriz Molina, Bill Andriopoulos, Pascal Maisonobe, Inna Prygova, Alessio Redaelli<\/td>\n<\/tr>\n<tr>\n<td><b>BoNT-As for Adult Spasticity and Cervical Dystonia: Cost-Effectiveness Analysis and the Cost of Response in the United Kingdom<\/b><br \/>\nKarissa Johnston, Natalya Danchenko, Talshyn Bolatova, John Whalen<\/td>\n<\/tr>\n<tr>\n<td><b>Economic outcomes in real-world use of botulinum toxin-A products for adult patients with upper limb spasticity: a UK perspective<\/b><br \/>\nLynne Turner-Stokes, Stephen Ashford, Jorge Jacinto, Klemens Fheodoroff, Natalya Danchenko, Pascal Maisonobe, Michael Williams, John Whalen<\/td>\n<\/tr>\n<tr>\n<td><b>Cost-Effectiveness of BoNT-A Products for Treatment of Pediatric Spasticity in the United Kingdom<\/b><br \/>\nNatalya Danchenko, Karissa Johnston, Talshyn Bolatova, John Whalen<\/td>\n<\/tr>\n<tr>\n<td><b>The Spasticity-Related Quality of Life 6-Dimensions Tool (SQOL-6D) in Upper Limb Spasticity: A First Psychometric Evaluation<\/b><br \/>\nLynne Turner-Stokes, Klemens Fheodoroff, Jorge Jacinto, Jeremy Lambert, Christine de la Loge, John Whalen, Pascal Maisonobe, Stephen Ashford<\/td>\n<\/tr>\n<tr>\n<td><b>AbobotulinumtoxinA in the Management of Hallux Valgus in Adult Patients: Results of a Randomized and Placebo-Controlled Phase II Trial<\/b><br \/>\nSelene G Parekh, David G Armstrong, Lawrence A DiDomenico, Babak Baravarian, Magali Volteau, Robert Silva<\/td>\n<\/tr>\n<tr>\n<td><b>Dosing from a Phase 3, Pivotal Study\u00a0of AbobotulinumtoxinA\u00a0Injection in Upper-Limb Muscles in Pediatric Patients with Cerebral Palsy<\/b><br \/>\nJoyce Oleszek, Ann Tilton, Jorge Carranza, Nigar Dursun, Marcin Bonikowski, Edward Dabrowski, Benjamin Regnault, Mauricio R. Delgado on behalf of the Dysport in PUL study group<\/td>\n<\/tr>\n<tr>\n<td><b>Efficacy and Safety of AbobotulinumtoxinA in Pediatric Lower Limb Spasticity: 2<\/b><b>nd<\/b><b>\u00a0Interim Results from a Phase IV, Prospective, Observational, Multicenter Study<\/b><br \/>\nMark Gormley, Edward Dabrowski, Ann Tilton, Asare Christian, Sarah Helen Evans, Pascal Maisonobe, Stefan Wietek<\/td>\n<\/tr>\n<tr>\n<td><b>Development of the Hygiene Extension Limb Position Pain (HELP) Tool to Monitor Waning of Clinical Efficacy in Patients with Spasticity or Cervical Dystonia Treated with Botulinum Toxins<\/b><br \/>\nAtul Patel, Stefan Wietek, Edward Dabrowski<\/td>\n<\/tr>\n<\/table>\n<p><b>R\u00e9f\u00e9rences<\/b><\/p>\n<ol>\n<li style=\"margin-bottom:3px\"><b>Esquenazi et al., TOXINS 2021. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Olughu et al., TOXINS 2021. The Systematic Approach to Developing a Cell-Free Platform Process for Recombinant Toxin Production.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Mason et al., TOXINS 2021. Digitisation of Toxin Development<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Pepeliaev S., TOXINS 2021. Automated fermentation platform for Toxin-based Therapeutics.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Allcock et al., TOXINS 2021. Quantity of Prabotulinumtoxin Type A in 100U vials.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Pryazhnikov et al., TOXINS 2021. Local cortical injection of AbobotulinumtoxinA (Dysport\u00ae) enhances the laser injury-induced microglial cell migration and process extension in in mice.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Carr\u00e9 et al., TOXINS 2021. 3D reconstruction and analysis of neuromuscular junction distribution in whole skeletal muscles in the rat using light-sheet microscopy.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Yeo et al., TOXINS 2021. BoNT Intoxication: Functional Genomics Reveals an Unexpected Trafficking Route.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Oehler et al., TOXINS 2021. Effects of recombinant botulinum neurotoxin type A1 on CFA-induced mechanical allodynia and sensory neurone responses to mechanical stimulation monitored with GCaMP fluorescence in mice.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Esquenazi et al., TOXINS 2021. Management of Symptom Re-Emergence in Patients Living with Spasticity and Cervical Dystonia: Findings from 2 Online Patient Surveys<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Esquenazi et al., TOXINS 2021. Patients Experiences of Symptom Re-Emergence: Findings from 2 Online Patient Surveys in Spasticity and Cervical Dystonia.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Jacinto et al., TOXINS 2021. Patient Perceptions of Spasticity and Treatment Satisfaction Over the Course of a Botulinum Neurotoxin A (BoNT-A) Treatment Cycle: An Ethnographic Study of Stroke Survivors.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Turner-Stokes et al., TOXINS 2021. Longitudinal Goal Attainment with Integrated Upper Limb Spasticity Management Including Botulinum Toxin A: Primary Results from the ULIS-III Study.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Jacinto et al., TOXINS 2021. Real-Life Data on the Time to Retreatment with Botulinum Toxin A in Upper Limb Spasticity Management.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Rosales et al., TOXINS 2021. Pain in Cervical Dystonia: A Meta-Analysis of Outcomes Following Treatment with AbobotulinumtoxinA in Randomized, Controlled Clinical Studies.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Esquenazi et al., TOXINS 2021. Impact of patient input on the study execution of an observational study assessing the effectiveness of abobotulinumtoxinA treatment in leg spasticity management in adults.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Dursun et al., TOXINS 2021. Improvement of Spastic Paresis and Cervical Dystonia Management: Assessment of Seven Years of the Innovative International Educational Program Ixcellence Network\u00ae.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Kestemont et al., TOXINS 2021. Long-Term Efficacy and Safety of Liquid Formulation AbobotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Placebo-Controlled and Open-Label Repeat Injection Study.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Smit et al., TOXINS 2021. Patient satisfaction with abobotulinumtoxinA for aesthetic use in the upper face: A Systematic literature review and post hoc analysis of the APPEAL study.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Johnston et al., TOXINS 2021. BoNT-As for Adult Spasticity and Cervical Dystonia: Cost-Effectiveness Analysis and the Cost of Response in the United Kingdom.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Turner-Stokes et al., TOXINS 2021. Economic outcomes in real-world use of botulinum toxin-A products for adult patients with upper limb spasticity: a UK perspective.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Danchenko et al., TOXINS 2021. Cost-Effectiveness of BoNT-A Products for Treatment of Pediatric Spasticity in the United Kingdom<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Turner-Stokes et al., TOXINS 2021. The Spasticity-Related Quality of Life 6-Dimensions Tool (SQOL-6D) in Upper Limb Spasticity: A First Psychometric Evaluation<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Parekh et al., TOXINS 2021. AbobotulinumtoxinA in the Management of Hallux Valgus in Adult Patients: Results of a Randomized and Placebo-Controlled Phase II Trial.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Oleszek et al., TOXINS 2021. Dosing from a Phase 3, Pivotal Study of AbobotulinumtoxinA Injection in Upper-Limb Muscles in Pediatric Patients with Cerebral Palsy.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Gormley et al., TOXINS 2021. Efficacy and Safety of AbobotulinumtoxinA in Pediatric Lower Limb Spasticity: 2nd Interim Results from a Phase IV, Prospective, Observational, Multicenter Study.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Patel et al., TOXINS 2021. Development of the Hygiene Extension Limb Position Pain (HELP) Tool to Monitor Waning of Clinical Efficacy in Patients with Spasticity or Cervical Dystonia Treated with Botulinum Toxins<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>TOXINS 2021 Virtual Congress. Virtual Congress Hall. TOXINS. Available at:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IH-6nBKA48xNxSUPi2oOWlUBTgxQcg7t07iLc3pHjOSJICQCSivoPrPe30pbZYxuqLX77841vmz0BM-Zp6nZcfKY9zmVpmoy3aE7lcZdf7Og7FdoyrjGDrMkGA8OdTtJetzRbwEm7HYYWRCVbwcV_ncXzeyUZq2zfNXZTw9WPcaVRMHSWJ9gy8ujRSCo_iW3eVQQghTrolmYZFMJz8joW3WFKUh_oFsbNd8mJGL7XtPLGcAgOrzMdupyx-RHW3Wr5vYhCL4L5YXSj_m_Cz4VrH-BoDOLWiPwHKGi1H_SPa3CLv-H7FWO_yTUQ5-y9BpHtcMhRFqdVBkWCd9iCqte1xoNrKm2WrUAWkfL2E-cJg2eH_kGwL4ySj-S-PBSWCLTsVB-32uXo6BVq2PpKOccxs6h-MXfAzt3VMt9vnH3Ujtz0w3bxk53VGWGUw5v830Sp5rZtHgmffwG-Xb4kPyRcKu0Wg6UDosez5APZA1JfyXwXqCL3mbUkEQ0fIe6J49S_Gugw021-MkG2bCR3VbFsiNG5U7vr9I3d6qTbV_EN8M=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/www.neurotoxins.org\/toxins-2021-virtual\/#:~:text=The%20TOXINS%202021%20virtual%20conference%20will%20provide%20participants%20with%20important,head%20and%20neck%2C%20limb%20dystonia%2C<\/a>. Accessed January 2021.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Mayo Clinic. Cervical Dystonia. Available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IH-6nBKA48xNxSUPi2oOWg71nJgH2f370mVU_Jxd8RRDivWB76HJQ35QydLfPUttJYj4iQkXf4WLEuNygV8Wn8CLJEoYCX_-FaaBwlWHvDO_ybIlEim3CAUN_H1383O5kHLZqk3nfKGz89fCaio8yAGeJtvLMeDCvBqqAH1wemHmi52TIsKtPmtQBSlXQzSo\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/www.mayoclinic.org\/diseases-conditions\/cervical-<\/a> dystonia\/symptoms-causes\/syc-20354123. Accessed December 2020.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>John Hopkins Medicine. Spasticity. Accessed: December 2020. Available at:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IH-6nBKA48xNxSUPi2oOWl-vgHMnMv-VE1MG-N1y0Lk9cn5VPG88i77YZ_79d-ANoqkFK6aPxjVjzPFSm0kMgYnfMwOg5gGSoewiumTVWDhqzMg2uXhXmMdRZTwDS80ryN_BfJ7RNV3i-B3hSFpAMzUZXRuEuTFdPjX3SKcxD_zxyjv6hbvgHTNnUsgZq9q4R6oW-VfOveVpC7zb2F00Jw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3a4ud5aTray-CCRx_wPOsrl-Y04mPeRREHxHrNlraTh44BuJ5YqA1MhxBJeEPCHJIEOGxxzo3RGFG948HdT-Mc4kmwj-Q6Wr1XlTTMtXAs7cN55QelOxtQ7HxR9m1yRnr-Y-SeKb3hKqkBVG5_Uwp9BbaWQEpoZpYMdh78PdiC8=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\u00a0diseases\/spasticity\">\u00a0diseases\/spasticity<\/a>. Accessed December 2020.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>American Association of Neurological Surgeons. Spasticity. Available at:<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1M-lEyjEj-sc7-BZEJmg4pm0g-YcJIh49VMe9vCN6TUnR_c14Rz3DCiwUEg7B80YrSKo3-oqxqRFi7rE-VlGUh21arZHqNfj6ubG66ZpiqW8tSOiU5wWTqVZd95Aii7B7nf8_KRb5CJDn6VaW75IiRT9GqDkvBBQqvvgE_f1_s-7BFitMVP33HL_DR1ZRf9sQYK_jpQXtilj9nKtueYysLcNJN18RqwyITyAVEA9h6s-Nynh_fUUa5AEpTdatxg5\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\u00a0https:\/\/www.aans.org\/Patients\/Neurosurgical-Conditions-and-Treatments\/Spasticity\">\u00a0https:\/\/www.aans.org\/Patients\/Neurosurgical-Conditions-and-Treatments\/Spasticity<\/a>. Accessed December 2020.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>American Association of Neurological Surgeons. Movement Disorders. Available at:<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1M-lEyjEj-sc7-BZEJmg4pm0g-YcJIh49VMe9vCN6TUnR_c14Rz3DCiwUEg7B80YrSKo3-oqxqRFi7rE-VlGUh21arZHqNfj6ubG66ZpiqXYW-hznpDxxny7gvtbxeGgpE9jJEe4FIwLa3mV3IRguZP4bQoBST4f1YVKB0x8LX8q0nJmZ065c6wUMx7LeT8eg4SDgygzxhqx6kBZ6mQuATrS1Tchphu0DWxFZrE8rx5SlAkonCWfs9daLpWKwCGPVAEpv7yejslL7HN_L0JiWw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\u00a0https:\/\/www.aans.org\/Patients\/Neurosurgical-Conditions-and-Treatments\/Movement-Disorders\">\u00a0https:\/\/www.aans.org\/Patients\/Neurosurgical-Conditions-and-Treatments\/Movement-Disorders<\/a>. Accessed December 2020.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Kuo C. Post-stroke Spasticity: A review of epidemiology, pathophysiology, and treatments. Int J Gerontol 2018;12:280-284.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Royal College of Physicians, British Society of Rehabilitation, \u201cSpasticity in adults: management using botulinum toxin. National Guidelines\u201d; 2018<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Claypool D, et al. Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota. Movement Disorders 1995;10: 608-614.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>National Institute of Neurological Disorders and Stroke. Dystonias Fact Sheet. Available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IH-6nBKA48xNxSUPi2oOWrr7UG7NKOsPOLYYS_WVBa3Ra8CytG-myHlD0nHY_zc4OjMA9H85JhyHmXjoNY_5hS9pAOisqvoeOHJ2yXyTzgXALIhdUkulr1vnwgQ84eI51SNT6tWpye6hnFExOArRkqgf4Zj9kh42wAB_IsWa5EvIs_enkwV08aj9mYM2wwNd4Aux8JOkSrSkTHEqCg6DxNAnhpI55W6OKN5hQ8eklB9NriabVyw1xdwA7J_yg99VovvOdsVCQHodCAqh6jPt7Q==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/www.ninih.gov\/Disorders\/Patient-Caregiver-Education\/Fact-Sheets\/Dystonias-Fact-Sheet.<\/a> Accessed December 2020.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>Castel\u00e3o M, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database of Systematic Reviews 2017;12:CD003633.<\/b><\/li>\n<li style=\"margin-bottom:3px\"><b>American Association of Neurological Surgeons. Dystonia. Available at<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1M-lEyjEj-sc7-BZEJmg4uRMpEN6TlqfowV1yW7zOgdIurUvCul-zBthpIKkr1rmKZYStHrex4nyZZsiyw_-F8EpdOF2T5HELipsmozArkPTT2gVWkgQbEaTlKHQDGR-a4YZnIEr9WG1nYRSjVxSNm0fmUQV027bJ3v6_nYgCb3Q7Dm3-Veb6pyDoRJsPhHQMlNs8N1uCTd75flWUYQB3SY7P0vxY3jub0K_EH4vnMLozRYNyx74RRt7aZWRxC80\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\u00a0http:\/\/www.aans.org\/Patients\/Neurosurgical-Conditions-and-Treatments\/Dystonia\">\u00a0http:\/\/www.aans.org\/Patients\/Neurosurgical-Conditions-and-Treatments\/Dystonia<\/a>. Accessed December 2020.<\/b><\/li>\n<\/ol>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=sO5LxH3JKlqsgJMps2qbOgcJDNUy8dn4URn53Fl4-IqAWzgLeT1AISrKaHl_VmHuMjZ-4zxK5l8wbi6kEww4LtXKoeGN1nd6o0mQ8vALPMWbOVBX544y6CuWm_A9i3NkiBSn_8eV-FZVKS1VxJjPVEhhTOiYzkIFLg0YlqN2yFEHbsb3oGWRCz9zjVf4WChKK9auhVJcVMrZNpTmhQj97w==\" title=\"Communique-de-presse-Ipsen-TOXINS-2021\" rel=\"nofollow noopener\">Communique-de-presse-Ipsen-TOXINS-2021<\/a><\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/OGFjOTE1YzAtMTFmOS00MTliLWEyYzMtZDZhMmIxODZjMmQzLTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1233,3556,3558],"tags":[],"class_list":["post-36542","press_release","type-press_release","status-publish","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","category-neuroscience-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>TOXINS 2021 : de nouvelles analyses de donn\u00e9es issues d\u2019\u00e9tudes pivotales de Phase III mettent en \u00e9vidence la dur\u00e9e d\u2019action prolong\u00e9e de Dysport\u00ae (abobotulinumtoxinA) dans cinq indications th\u00e9rapeutiques<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TOXINS 2021 : de nouvelles analyses de donn\u00e9es issues d\u2019\u00e9tudes pivotales de Phase III mettent en \u00e9vidence la dur\u00e9e d\u2019action prolong\u00e9e de Dysport\u00ae (abobotulinumtoxinA) dans cinq indications th\u00e9rapeutiques\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-31T06:02:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/OGFjOTE1YzAtMTFmOS00MTliLWEyYzMtZDZhMmIxODZjMmQzLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"TOXINS 2021 : de nouvelles analyses de donn\u00e9es issues d\u2019\u00e9tudes pivotales de Phase III mettent en \u00e9vidence la dur\u00e9e d\u2019action prolong\u00e9e de Dysport\u00ae (abobotulinumtoxinA) dans cinq indications th\u00e9rapeutiques\",\"datePublished\":\"2021-01-15T16:01:00+00:00\",\"dateModified\":\"2023-08-31T06:02:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/\"},\"wordCount\":2445,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OGFjOTE1YzAtMTFmOS00MTliLWEyYzMtZDZhMmIxODZjMmQzLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Corporate\",\"Neuroscience\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/\",\"name\":\"TOXINS 2021 : de nouvelles analyses de donn\u00e9es issues d\u2019\u00e9tudes pivotales de Phase III mettent en \u00e9vidence la dur\u00e9e d\u2019action prolong\u00e9e de Dysport\u00ae (abobotulinumtoxinA) dans cinq indications th\u00e9rapeutiques\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OGFjOTE1YzAtMTFmOS00MTliLWEyYzMtZDZhMmIxODZjMmQzLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2021-01-15T16:01:00+00:00\",\"dateModified\":\"2023-08-31T06:02:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/OGFjOTE1YzAtMTFmOS00MTliLWEyYzMtZDZhMmIxODZjMmQzLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OGFjOTE1YzAtMTFmOS00MTliLWEyYzMtZDZhMmIxODZjMmQzLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TOXINS 2021 : de nouvelles analyses de donn\u00e9es issues d\u2019\u00e9tudes pivotales de Phase III mettent en \u00e9vidence la dur\u00e9e d\u2019action prolong\u00e9e de Dysport\u00ae (abobotulinumtoxinA) dans cinq indications th\u00e9rapeutiques\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TOXINS 2021 : de nouvelles analyses de donn\u00e9es issues d\u2019\u00e9tudes pivotales de Phase III mettent en \u00e9vidence la dur\u00e9e d\u2019action prolong\u00e9e de Dysport\u00ae (abobotulinumtoxinA) dans cinq indications th\u00e9rapeutiques","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/","og_locale":"fr_FR","og_type":"article","og_title":"TOXINS 2021 : de nouvelles analyses de donn\u00e9es issues d\u2019\u00e9tudes pivotales de Phase III mettent en \u00e9vidence la dur\u00e9e d\u2019action prolong\u00e9e de Dysport\u00ae (abobotulinumtoxinA) dans cinq indications th\u00e9rapeutiques","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/","og_site_name":"Global","article_modified_time":"2023-08-31T06:02:07+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/OGFjOTE1YzAtMTFmOS00MTliLWEyYzMtZDZhMmIxODZjMmQzLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"TOXINS 2021 : de nouvelles analyses de donn\u00e9es issues d\u2019\u00e9tudes pivotales de Phase III mettent en \u00e9vidence la dur\u00e9e d\u2019action prolong\u00e9e de Dysport\u00ae (abobotulinumtoxinA) dans cinq indications th\u00e9rapeutiques","datePublished":"2021-01-15T16:01:00+00:00","dateModified":"2023-08-31T06:02:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/"},"wordCount":2445,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OGFjOTE1YzAtMTFmOS00MTliLWEyYzMtZDZhMmIxODZjMmQzLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Communiqu\u00e9 de presse","Corporate","Neuroscience"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/","name":"TOXINS 2021 : de nouvelles analyses de donn\u00e9es issues d\u2019\u00e9tudes pivotales de Phase III mettent en \u00e9vidence la dur\u00e9e d\u2019action prolong\u00e9e de Dysport\u00ae (abobotulinumtoxinA) dans cinq indications th\u00e9rapeutiques","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OGFjOTE1YzAtMTFmOS00MTliLWEyYzMtZDZhMmIxODZjMmQzLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2021-01-15T16:01:00+00:00","dateModified":"2023-08-31T06:02:07+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/OGFjOTE1YzAtMTFmOS00MTliLWEyYzMtZDZhMmIxODZjMmQzLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OGFjOTE1YzAtMTFmOS00MTliLWEyYzMtZDZhMmIxODZjMmQzLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/toxins-2021-de-nouvelles-analyses-de-donnees-issues-detudes-pivotales-de-phase-iii-mettent-en-evidence-la-duree-daction-prolongee-de-dysport-abobotulinumtoxina-dans-cinq-in\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"TOXINS 2021 : de nouvelles analyses de donn\u00e9es issues d\u2019\u00e9tudes pivotales de Phase III mettent en \u00e9vidence la dur\u00e9e d\u2019action prolong\u00e9e de Dysport\u00ae (abobotulinumtoxinA) dans cinq indications th\u00e9rapeutiques"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":2,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36542\/revisions"}],"predecessor-version":[{"id":36544,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/36542\/revisions\/36544"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=36542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=36542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=36542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}